DMK
ARLZ

David M. Knott’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

David M. Knott’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-37,698
Closed -$166K – 83
2016
Q4 		$166K Hold
37,698
– – 0.08% 45
2016
Q3 		$183K Hold
37,698
– – 0.09% 41
2016
Q2 		$124K Buy
+37,698
New +$142K 0.03% 61

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

David M. Knott's ARLZ Position: Q1 2017 in Review

David M. Knott sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q1 2017, closing a stake of 37,698 shares — an estimated $166K sold.

David M. Knott first reported a position in ARLZ in Q2 2016 and held it in 3 quarters. The position peaked at $183K in Q3 2016. 78 funds tracked by Wall St. Rank hold ARLZ as of Q1 2017.

  • David M. Knott reported no remaining Aralez Pharmaceuticals Inc. position as of Q1 2017 after selling out during the quarter.
  • David M. Knott sold 37,698 Aralez Pharmaceuticals Inc. shares in Q1 2017, an estimated $166K.
  • David M. Knott first reported a position in Aralez Pharmaceuticals Inc. in Q2 2016 and held it in 3 quarters.
  • David M. Knott's Aralez Pharmaceuticals Inc. position peaked at $183K in Q3 2016.
  • 78 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q1 2017.

Based on David M. Knott's 13F filing for Q1 2017, filed 12 May 2017.